All In Biotech

Drug Trial Radar · NCT02684032

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

PHASE 1B STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AND EITHER LETROZOLE OR FULVESTRANT IN WOMEN WITH METASTATIC OR LOCALLY ADVANCED/RECURRENT BREAST CANCER (MBC)

Last checked: Nov 19, 2026Latest source record: Jul 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

141

Actual

Start

Jun 14, 2016

Primary completion

Jan 19, 2022

Study completion Jan 19, 2022

Sponsor

Lead sponsor
Celcuity IncIndustry
Sponsor type
Industry
First posted
Feb 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have a dose escalation to identify the maximum tolerated dose (MTD) of the combination of gedatolisib plus palbociclib/fulvestrant and gedatolisib plus palbociclib/letrozole and expansion to estimate the objective response rate (OR) of the combination of gedatolisib plus palbociclib/letrozole or palbociclib/fulvestrant.

Conditions

  • Breast Cancer

Interventions

  • GedatolisibDrug

    Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.

  • PalbociclibDrug

    Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.

  • LetrozoleDrug

    Letrozole at 2.5 mg daily

  • FulvestrantDrug

    Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicitiesTime frame: up to 28 days
  2. Objective response rate observed in patients in the dose expansion portionTime frame: 16 weeks
  3. Objective response rate observed in patients in the dose expansion portionTime frame: 16 weeks

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.

    Corona, California

  • Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.

    Fountain Valley, California

  • Keck Hospital of USC - Norris Healthcare Center (HC3)

    Los Angeles, California

  • Keck Hospital of USC

    Los Angeles, California

  • LAC+USC Medical Center

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center / Investigational Drug Services

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.

    Riverside, California

  • UCSF - Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • UCSF - Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AiP)

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)

    Aurora, Colorado

  • University of Colorado Hospital - Clinical Trials Office (CTO)

    Aurora, Colorado

  • University of Colorado Hospital- Anschutz Cancer Pavilion (ACP)

    Aurora, Colorado

  • Moffitt Cancer Center Richard M Schulze Family Foundation Outpatient Center at McKinley Campus

    Tampa, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Emory University Hospital Midtown

    Atlanta, Georgia

  • Emory University Hospital

    Atlanta, Georgia

  • The Emory Clinic

    Atlanta, Georgia

  • Winship Cancer Institute

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Karmanos Cancer Institute

    Farmington Hills, Michigan

  • UNC Cancer Hospital Infusion Pharmacy

    Chapel Hill, North Carolina

  • UNC Hospitals, The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • The Ohio State University Wexner Medical Center James Cancer Hospital

    Columbus, Ohio

  • Stefanie Spielman Comprehensive Breast Cancer

    Columbus, Ohio

  • Thomas Jefferson University - Clinical and Regulatory

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Vanderbilt Breast Center at One Hundred Oaks

    Nashville, Tennessee

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • U.T. MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Seattle Cancer Care Alliance (SCCA) Investigational Drug Services

    Seattle, Washington

  • Seattle Cancer Care Alliance

    Seattle, Washington

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.